Navigation Links
Nile Therapeutics Announces Dosing in Phase IIa Study of CD-NP in Heart Failure Patients
Date:7/11/2008

SAN FRANCISCO, July 11 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX), today announced that it has dosed the first acute setting heart failure patient in its Phase IIa, multi-center, open-label, ascending dose clinical study of the company's lead product candidate, CD-NP, a novel chimeric natriuretic peptide, in development for the treatment of acute decompensated heart failure.

The primary objective of the Phase IIa study is to assess hemodynamic effects of intravenous infusions of CD-NP in patients with heart failure. Key assessments include measurement of pulmonary capillary wedge pressure (PCWP), plasma cGMP, a secondary messenger of the target receptor, blood pressure, heart rate, serum potassium and renal function. Nile expects up to 30 heart failure patients will be enrolled in the trial.

Results from the Phase Ia study in 22 healthy volunteers were consistent with several pre-clinical findings, including that CD-NP was associated with increased levels of plasma cGMP, preserved renal function, increased natriuresis and diuresis with minimal effect on mean arterial pressure. In parallel with the Phase IIa study, Nile is completing its Phase Ib study of CD-NP. The primary objectives of the Phase Ib study are to assess the safety and tolerability of intravenous infusions of CD-NP in patients with heart failure. Results from both the Phase Ib and Phase IIa trials are expected to be available in 2008.

"We are pleased to have reached this important corporate milestone and to be able to begin this Phase II trial of CD-NP in heart failure patients," said Peter Strumph, Chief Executive Officer of Nile. "We look forward to rapidly enrolling this Phase II trial and to further investigating the clinical e
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Echo Therapeutics Initiates Clinical Study of Its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
2. Silence Therapeutics Announces Board Changes
3. Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial
4. Data Presented at American Headache Societys Annual Scientific Meeting Show Primary Endpoint Met as Well as Improvement on Important Secondary Endpoints in Phase IIb Acute Migraine Trial of TorreyPines Therapeutics Tezampanel
5. TorreyPines Therapeutics to Host Webinar at 11 a.m. EDT Today on the Opportunity for Treating Chronic Pain, Migraine and Muscle Spasticity Through Inhibition of Neurotransmitter Glutamate
6. CV Therapeutics Announces Archives of Internal Medicine Publication of Study Showing 20 Percent of Heart Attack Patients in Premier Registry Experienced Angina at One Year
7. Pilot Therapeutics Announces Relaunch as Gene Smart(TM) Health
8. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
9. PTC Therapeutics Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity
10. Duska Therapeutics Licenses Portfolio of Heart Failure Drugs From Duke and Johns Hopkins
11. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 Research and ... Hypodermic Needles Market 2014-2018" report to their offering. ... A hypodermic needle is a hollow needle commonly used ... or or to extract fluids from it. A hypodermic ... to inject substances that cannot be ingested. Hypodermic needles ...
(Date:7/11/2014)... 11, 2014 Research and Markets ( ... "Immunoprotein Diagnostic Testing Market - Forecasts to ... of 6% and is expected to be valued ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... has been segmented according to immunoprotein types which ...
(Date:7/10/2014)... NEWS, Virginia , 11. Juli ... Hersteller von Kameras für die molekulare ... (MBI/BSGI), hat heute die CE-Zulassung für ... dem CE-Zeichen kann Dilon das Produkt ... Vertriebsbereich auf den Großteil der europäischen ...
Breaking Medicine Technology:Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 3Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2
... 6, 2012   Heska Corporation (NASDAQ: ... and other specialty veterinary products , today announced that ... practices research, tools and metrics for patent analysis and ... Heska,s Science Strength in the top 50 of the ...
...  The United States Patent & Trademark Office (USPTO) has ... ) that the USPTO has rejected all claims by ... 7,357,891 (the ,891 Patent) which is currently being asserted ... (Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO ) ...
Cached Medicine Technology:The Patent Board Ranks Heska's Science Strength in Biotechnology Industry Top 50 2The Patent Board Ranks Heska's Science Strength in Biotechnology Industry Top 50 3US Patent Office Rejection of All Claims in Final Asserted MonoSol Patent Further Supports BioDelivery Sciences' Position 2US Patent Office Rejection of All Claims in Final Asserted MonoSol Patent Further Supports BioDelivery Sciences' Position 3
(Date:7/13/2014)... The Pearland, Texas location of The Little Gym, a gymnastics ... 12 years of age that offers everything from gymnastics, dance, ... Camps, is now under new ownership. , Kevin Berry comes ... over six years at The Little Gym of Bellaire in ... has over ten years of experience working with children, including ...
(Date:7/13/2014)... 2014 Max International has ... will be the featured guest at its Charity Exhibition ... Rico. Attendees will learn about Max’s health products ... exhibition basketball games and perform in a 3 point ... health- and energy-boosting supplements , has recently announced former ...
(Date:7/13/2014)... device developed at Cedars-Sinai can provide early detection ... and are a classic sign of Alzheimer,s disease, ... clinical trial in Australia. , The researchers will ... presentation at the Alzheimer,s Association International Conference 2014 ... conference organizers to participate in a "breaking news" ...
(Date:7/13/2014)... OH (PRWEB) July 13, 2014 A ... Wright & Schulte LLC to provide consumers with the ... sometimes accompany use of the blood-thinning medication, as well ... pending in courts around the country. The law ... who may have suffered from life-threatening internal bleeding and ...
(Date:7/13/2014)... Ann Arbor, MI (PRWEB) July 13, 2014 ... online learning program he has just launched at http://www.HealthYourself101.com ... management of visceral obesity. , Power has set out ... and its ill effects that’s actually – dare we say ... , “The program,” says Power, “aims to engage the remote ...
Breaking Medicine News(10 mins):Health News:The Little Gym of Pearland, TX Now Under New Ownership and Management 2Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 2Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 3Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 4Health News:Study of noninvasive retinal imaging device presented at Alzheimer's conference 2Health News:Study of noninvasive retinal imaging device presented at Alzheimer's conference 3Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 2Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 3Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 4Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 2Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 3Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 4
... to treat injury, stroke and even Alzheimer,s, experts say , , ... study involving mice suggests the brain,s own stem cells may ... These neural stem cells work by protecting existing cells and ... the University of California, Irvine, were able to bring the ...
... As the seventh leading cause of cancer death worldwide, ... ethnic group and gender. Esophageal cancer is thought to ... interact with the host genome. Researchers have long been ... been conducted on gene-environment interaction and gene polymorphisms for ...
... remove part or all of the colon (colectomy) for people ... researchers in a study published on bmj.com today. ... of the intestine and includes ulcerative colitis and Crohns disease. ... are affected and many people will require colectomy at some ...
... MAP,Pharmaceuticals, Inc. (Nasdaq: MAPP ), ... of a Phase 2a clinical trial evaluating,MAP0005 ... chronic obstructive,pulmonary disease (COPD). MAP0005 is ... long-acting,beta2-agonist delivered to the respiratory tract using ...
... BPUR ) announced today that the trading symbol for ... BPUR at the open of the market on,Wednesday, October ... revert to the following ticker symbols: BPREW reverting to ... Biopure Corporation Biopure Corporation develops, manufactures and ...
... HRAL) announced today that it has formed an alliance ... Stores (NYSE: WMT ) to help,conquer hearing loss ... Starting November 15, 2007, HearAtLast customers will receive a,$100.00 ... with,their American Express card. The promotion is scheduled to ...
Cached Medicine News:Health News:Stem Cells Restore Memory in Mice 2Health News:Stem Cells Restore Memory in Mice 3Health News:ADH2 and ALDH2 are associated with esophageal cancer 2Health News:Threshold for bowel surgery may be too high, warn experts 2Health News:MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma 2Health News:MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma 3Health News:MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma 4Health News:Biopure's Stock Symbol Reverts to BPUR 2Health News:HearAtLast Teams Up with American Express and Wal-Mart to Conquer Hearing Loss 2Health News:HearAtLast Teams Up with American Express and Wal-Mart to Conquer Hearing Loss 3Health News:HearAtLast Teams Up with American Express and Wal-Mart to Conquer Hearing Loss 4
... SET LNOP Blue Sensor is the first ... The LNOP Blue sensor is the first ... for cyanotic infants and children. Cyanotic ... conditions for reliable and accurate pulse oximetry, ...
Inquire...
... The Trinity Biotech Captia™ Varicella- Zoster ... (ELISA) is intended for the detection and ... in human sera. Individual serum specimens may ... status. Paired sera, acute and convalescent, may ...
ELISA kit for Varicella-zoster IgG....
Medicine Products: